Skip to content

A clinical trial for the treatment of severe COVID-19 disease progression is funded by the BMBF

No quod sanctus instructior ius, et intellegam interesset duo. Vix cu nibh gubergren dissentias. His velit veniam habemus ne. No doctus neglegentur vituperatoribus est, qui ad ipsum oratio. Ei duo dicant facilisi, qui at harum democritum consetetur.

“Unfortunately we have to expect that people will continue to fall ill with COVID-19 in the foreseeable future. We therefore urgently need to increase our arsenal of effective drugs,” said Federal Research Minister Anja Karliczek. Therefore safe and effective drugs are needed to treat those who become sick.

For that reason the German Federal Ministry of Education and Research (BMBF) is funding research into drugs against COVID-19. With this aim in mind the two HiGHmed partners Charité and the University Hospital Würzburg (UKW) as well as the associated HiGHmed-partner Unfallkrankenhaus Berlin (UKB) have joined forces with the Berlin Institute of Health (BIH), Bayer and the University Hospital Leipzig (UKL) for a multi-site COVID-19 study. In close cooperation with HiGHmed e.V. the joint project application was submitted to the BMBF and is now one of the eight projects to be funded. For the official press release of the BIH click here.


Leave a Comment